Codexis, Inc.

$1.63

+$0.02 (+1.24%)

Jan 5, 2026

Price History (1Y)

Analysis

Codexis, Inc. is a biotechnology company operating in the healthcare sector with a market capitalization of $147.23 million and 188 employees. The company's revenue (TTM) stands at $52.93 million. The company exhibits negative profitability, with gross margin, operating margin, and profit margin all below zero: -20.2%, -220.3%, and -120.8% respectively. Returns on equity (-114.3%) and assets (-27.4%) are also negative. The balance sheet is characterized by significant debt ($68.62 million) and a substantial cash position ($58.70 million), resulting in a debt-to-equity ratio of 178.03. The company's valuation metrics include a forward P/E ratio of -3.33, EV/EBITDA of -2.85, price to book of 3.82, and price to sales of 2.78. Revenue growth (YoY) is -33.0%, while earnings growth (YoY) is not available. The dividend yield is N/A and the payout ratio is 0.0%.

This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.

About Codexis, Inc.

Codexis, Inc. provides enzymatic solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, and enhance novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California.

Visit website →

Key Statistics

Market Cap
$147.23M
P/E Ratio
N/A
52-Week High
$5.43
52-Week Low
$1.52
Avg Volume
1.09M
Beta
2.44

Company Info

Exchange
NMS
Country
United States
Employees
188